Very Low-Calorie Diet Plus Exercise Does Not Reduce Hip Pain in OA
THURSDAY, Aug. 7, 2025 -- For adults with hip osteoarthritis and overweight or obesity, a very low-calorie diet (VLCD) plus exercise does not reduce hip pain, but does improve most secondary outcomes, according to a study published online Aug. 5 in the Annals of Internal Medicine.
Michelle Hall, Ph.D., M.D., from The University of Sydney, and colleagues examined the efficacy of a weight loss diet added to exercise on change in hip pain in a two-group superiority randomized trial involving 101 adults with hip osteoarthritis and overweight or obesity. The exercise-only group and VLCD-plus-exercise group were provided with a six-month home exercise program via five telehealth consultations; the VLCD-plus-exercise group also received six telehealth consultations.
The researchers found that the VLCD-plus-exercise group lost 8.5 percent more weight than the exercise-only group, but VLCD plus exercise was not more effective for change in hip pain severity at six months. For other secondary outcomes at six months, between-group differences favored VLCD plus exercise, apart from the Hip Disability and Osteoarthritis Outcome Score (HOOS) pain and function. Weight, body mass index, HOOS pain and function, and overall hip improvement favored VLCD plus exercise at 12 months, but quality of life and physical activity did not.
"In persons with hip osteoarthritis and overweight or obesity, adding a VLCD to exercise that resulted in substantial weight loss did not affect the primary outcome of hip pain severity relative to exercise alone at either six or 12 months," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Oral Orforglipron Yields Greater Weight Reductions Than Placebo
THURSDAY, Sept. 25, 2025 -- For adults with obesity who do not have diabetes, the oral glucagon-like peptide-1 receptor agonist orforglipron yields significantly greater...
Oral Semaglutide Effective for Weight Loss in Overweight or Obesity
THURSDAY, Sept. 25, 2025 -- Oral semaglutide (25 mg) is effective for weight loss in adults with overweight or obesity without diabetes, according to a study published online...
Guidance Issued on Impact, Management of Potassium, Phosphorus in CKD
THURSDAY, Sept. 25, 2025 -- Guidance is presented for understanding the impact of potassium and phosphorus additives on people with chronic kidney disease (CKD) and managing their...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.